Phaseline

Targets › RIPR

RIPR: drug programs, companies and trials

1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: the race on RIPR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of OxfordRH5.1
Soluble RIPR EGF-CyRPA fusion protein vaccine
RH5, RIPR, CYRPAPhase 2Malaria,FalciparumMar 2027

Conditions

Malaria,Falciparum (2)

Modalities

protein or peptide (1)

Companies

University of Oxford (1)

Related targets

RH5 (1) CYRPA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.